Figure 3

Analysis of the modes of action of pimprinethine, WS-30581 A and WS-30581 against EV71. (A-B) Analysis of the effective stage. The RD cells were incubated under serial 2-fold dilutions of tested compounds before, simultaneously or after EV71 (100 TCID₅₀) inoculation. Antiviral effects were detected by measuring cell viability (A) and the progeny virus yields (80 μM) (B) after 48 h of infection. (C) Analysis of the effects on EV71 adsorption. Mock- or 160 μM pimprinethine, 80 μM WS-30581A and 80 μM WS-30581 B-treated EV71 (10⁴TCID50) was inoculated onto RD cells and adsorbed for 2 h, the infected cells were harvested and then subjected to virus titrations using the TCID₅₀ method. (D) The effects on EV71 release from RD cells. RD cells infected with 100 TCID₅₀ of EV71 were incubated with tested compounds for 12 h, both of cells and supernatants (intra- and extracellular), or one of which was harvested separately for determination of virus yield. Mock: no infection; VC, virus control. Values represent the means ± SDs of three independent experiments. *P <0.05, compared with virus control group.